



Clinical trial results:

A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)

Summary

EudraCT number	2012-002255-42
Trial protocol	GB
Global end of trial date	10 November 2021

Results information

Result version number	v1 (current)
This version publication date	15 October 2023
First version publication date	15 October 2023

Trial information

Trial identification

Sponsor protocol code	MK-3222-010
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01722331
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Sun Pharmaceutical Industries Limited
Sponsor organisation address	Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai, India, 400063
Public contact	Head-Clinical Development, Sun Pharmaceutical Industries Limited, +91 2266455645 ext. 5689, Clinical.Trial@sunpharma.com
Scientific contact	Head-Clinical Development, Sun Pharmaceutical Industries Limited, +91 2266455645 ext. 5689, Clinical.Trial@sunpharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 October 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	28 October 2015
Global end of trial reached?	Yes
Global end of trial date	10 November 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Primary Efficacy Objective: To assess the efficacy of tildrakizumab (SCH-900222/MK-3222) (hereafter referred to as MK-3222) compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of subjects with at least 75% improvement in the Psoriasis Area and Severity Index from baseline (PASI 75 response), and the proportion of subjects with a Physician's Global Assessment (PGA) score of "clear" or "minimal", with at least a 2 grade reduction from baseline, at Week 12.

Primary Safety/Tolerability Objective: To assess the safety/tolerability of tildrakizumab (MK-3222) in subjects with moderate-to-severe chronic plaque psoriasis at Week 12.

Extension Study:

To assess long-term safety and tolerability of tildrakizumab (MK-3222) in subjects with moderate-to-severe chronic plaque psoriasis for a minimum of 4 years.

Protection of trial subjects:

The following provisions are within the study protocol to ensure adequate protection of subjects:

1. Each subject will be monitored for the occurrence of SAEs immediately after signing informed consent and will be followed up for adverse events (AEs, SAEs, ECIs) for upto 20 weeks after the last visit in the treatment period (base or extension)
2. Subject's right to withdraw his/her consent at any time during the trial with or without a stated reason
3. It is the right and the duty of the investigator or subinvestigator to stop treatment in any case in which emerging effects are of unacceptable risk to the individual subject
4. All subjects were screened for presence of latent or untreated TB infections, HIV, hepatitis B surface antigen, hepatitis C virus, chronic disease, organ dysfunction, use of prohibited medications and presence of any other such conditions to ensure to minimize the potential risk to study subjects prior to enrollment
-Every subject will be monitored for the occurrence of SAEs immediately after the subject has signed informed consent form
5. The study has constituted a DSMB for monitoring the safety of the trial subjects during the study

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 December 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 88
Country: Number of subjects enrolled	Canada: 192
Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	Japan: 158
Country: Number of subjects enrolled	United States: 326
Worldwide total number of subjects	772
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	697
From 65 to 84 years	75
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 977 subjects were screened for the study, of which 205 were not randomized.

Period 1

Period 1 title	Base study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	No
------------------------------	----

Arm title	Placebo
------------------	---------

Arm description:

Placebo administered SC once a week at Weeks 0 and 4

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching placebo to tildrakizumab administered SC

Arm title	Tildrakizumab 100
------------------	-------------------

Arm description:

Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks

Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Tildrakizumab 100 mg administered SC

Arm title	Tildrakizumab 200
------------------	-------------------

Arm description:

Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Tildrakizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:
Tildrakizumab 200 mg administered SC

Number of subjects in period 1	Placebo	Tildrakizumab 100	Tildrakizumab 200
Started	155	309	308
Completed	124	250	264
Not completed	31	59	44
Adverse event, serious fatal	-	-	1
Physician decision	2	6	1
Consent withdrawn by subject	10	14	11
Non-Compliance with Study Drug	-	2	1
Adverse event, non-fatal	1	3	10
Progressive Disease	1	1	-
Pregnancy	1	-	1
Protocol Violation	1	1	4
Other Protocol Specified Criteria	3	11	7
Lost to follow-up	4	9	4
Lack of efficacy	8	12	4

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description: Placebo administered SC once a week at Weeks 0 and 4	
Reporting group title	Tildrakizumab 100
Reporting group description: Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks	
Reporting group title	Tildrakizumab 200
Reporting group description: Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.	

Reporting group values	Placebo	Tildrakizumab 100	Tildrakizumab 200
Number of subjects	155	309	308
Age categorical Units: Subjects			

Age continuous Units: years median full range (min-max)	47.5 19 to 76	46.0 18 to 82	48.0 18 to 76
Gender categorical Units: Subjects			
Female	55	102	82
Male	100	207	226

Reporting group values	Total		
Number of subjects	772		
Age categorical Units: Subjects			

Age continuous Units: years median full range (min-max)	-		
Gender categorical Units: Subjects			
Female	239		
Male	533		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Placebo administered SC once a week at Weeks 0 and 4	
Reporting group title	Tildrakizumab 100
Reporting group description: Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks	
Reporting group title	Tildrakizumab 200
Reporting group description: Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.	

Primary: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12

End point title	Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12
End point description:	
End point type	Primary
End point timeframe: Week 12	

End point values	Placebo	Tildrakizumab 100	Tildrakizumab 200	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	309	308	
Units: Percentage of Participant				
number (not applicable)	5.8	63.8	62.3	

Statistical analyses

Statistical analysis title	CMH analysis of PASI75 Response at Week 12
Comparison groups	Tildrakizumab 100 v Placebo
Number of subjects included in analysis	463
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	CMH analysis of PASI75 Response at Week 12
----------------------------	--

Comparison groups	Tildrakizumab 200 v Placebo
Number of subjects included in analysis	462
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12

End point title	Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12
-----------------	--

End point description:

End point type	Secondary
End point timeframe:	Week 12

End point values	Placebo	Tildrakizumab 100	Tildrakizumab 200	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	309	308	
Units: Percentage of Participant				
number (not applicable)	7.1	57.9	59.1	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With PASI-90 Response At Week 12

End point title	Percentage of Participants With PASI-90 Response At Week 12
-----------------	---

End point description:

End point type	Secondary
End point timeframe:	Week 12

End point values	Placebo	Tildrakizumab 100	Tildrakizumab 200	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	309	308	
Units: Percentage of Participants				
number (not applicable)	2.6	34.6	35.4	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with PASI-100 Response at Week 12

End point title	Percentage of Participants with PASI-100 Response at Week 12
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100	Tildrakizumab 200	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	309	308	
Units: Percentage of Participants With PASI-100				
number (not applicable)	1.3	13.9	14.0	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Participant DLQI Score at Week 12

End point title	Change From Baseline in the Participant DLQI Score at Week 12
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12

End point values	Placebo	Tildrakizumab 100	Tildrakizumab 200	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	154	309	308	
Units: Score on a scale				
least squares mean (confidence interval 95%)	-2.3 (-3.1 to -1.5)	-9.8 (-10.4 to -9.1)	-10.0 (-10.7 to -9.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with DLQI Score of 0 or 1 at Week 12

End point title	Percentage of Participants with DLQI Score of 0 or 1 at Week 12
End point description:	
End point type	Secondary
End point timeframe:	
Week 12	

End point values	Placebo	Tildrakizumab 100	Tildrakizumab 200	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	150	304	299	
Units: Percentage of Participants				
number (not applicable)	5.3	41.5	44.2	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 84 weeks including a 20-week follow-up period.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Tilrakizumab 200 mg (Part 1)
-----------------------	------------------------------

Reporting group description:

Tilrakizumab 200 mg administered once a week at Weeks 0 and 4.

Reporting group title	Tilrakizumab 200 mg (Part 2)
-----------------------	------------------------------

Reporting group description:

Tilrakizumab 200 mg administered once a week at Week 16 (includes placebo participants re-randomized at Week 12 to receive tilrakizumab 200 mg)

Reporting group title	Tilrakizumab 100 mg (Part 2)
-----------------------	------------------------------

Reporting group description:

Tilrakizumab 100 mg administered once a week at Week 16 (includes placebo participants re-randomized at Week 12 to receive Tilrakizumab 100 mg). Includes 1 participant who did not enter Part 2, but received an unscheduled dose at Week 12.

Reporting group title	Tilrakizumab 200 mg (Part 3)
-----------------------	------------------------------

Reporting group description: -

Reporting group title	Tilrakizumab 100 mg (Part 3)
-----------------------	------------------------------

Reporting group description: -

Reporting group title	Placebo (Part 1)
-----------------------	------------------

Reporting group description:

Placebo administered once a week at Weeks 0 and 4.

Reporting group title	Tilrakizumab 100 mg (Part 1)
-----------------------	------------------------------

Reporting group description:

Tilrakizumab 100 mg administered once a week at Weeks 0 and 4.

Serious adverse events	Tilrakizumab 200 mg (Part 1)	Tilrakizumab 200 mg (Part 2)	Tilrakizumab 100 mg (Part 2)
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 308 (2.60%)	8 / 370 (2.16%)	7 / 374 (1.87%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign biliary neoplasm			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			

subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carcinoma in situ of skin			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aneurysm			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 308 (0.32%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine haemorrhage			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 308 (0.32%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Suicide attempt			
subjects affected / exposed	1 / 308 (0.32%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lower limb fracture			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 308 (0.32%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	1 / 308 (0.32%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebellar infarction			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar infarction			

subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia neonatal			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular fibrosis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Diverticulum			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food poisoning			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 308 (0.32%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salivary gland enlargement			
subjects affected / exposed	1 / 308 (0.32%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rotator cuff syndrome			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Epiglottitis			
subjects affected / exposed	1 / 308 (0.32%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone tuberculosis			
subjects affected / exposed	0 / 308 (0.00%)	1 / 370 (0.27%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	1 / 374 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			

subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 308 (0.00%)	0 / 370 (0.00%)	0 / 374 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Tildrakizumab 200 mg (Part 3)	Tildrakizumab 100 mg (Part 3)	Placebo (Part 1)
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 360 (5.83%)	14 / 316 (4.43%)	1 / 154 (0.65%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign biliary neoplasm			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 360 (0.00%)	2 / 316 (0.63%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	1 / 360 (0.28%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carcinoma in situ of skin			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Squamous cell carcinoma of skin subjects affected / exposed	2 / 360 (0.56%)	2 / 316 (0.63%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aneurysm			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	2 / 360 (0.56%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine haemorrhage			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lower limb fracture			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			

subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebellar infarction			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lacunar infarction			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	1 / 154 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Anaemia neonatal			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular fibrosis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food poisoning			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Salivary gland enlargement			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rotator cuff syndrome			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Epiglottitis			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	2 / 360 (0.56%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone tuberculosis			
subjects affected / exposed	0 / 360 (0.00%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	1 / 360 (0.28%)	0 / 316 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 360 (0.00%)	1 / 316 (0.32%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Tildrakizumab 100 mg (Part 1)		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 309 (1.62%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign biliary neoplasm			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Basal cell carcinoma			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bowen's disease			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carcinoma in situ of skin			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Aneurysm			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Uterine haemorrhage			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	1 / 309 (0.32%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sleep apnoea syndrome			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			

Suicide attempt			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Lower limb fracture			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 309 (0.32%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebellar infarction			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lacunar infarction			

subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Presyncope			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sciatica			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia neonatal			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Cataract			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Macular fibrosis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Diverticulum			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Food poisoning			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Salivary gland enlargement			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	1 / 309 (0.32%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 309 (0.32%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Rotator cuff syndrome			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Epiglottitis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	1 / 309 (0.32%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bone tuberculosis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diverticulitis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis salmonella			

subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	0 / 309 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Tildrakizumab 200 mg (Part 1)	Tildrakizumab 200 mg (Part 2)	Tildrakizumab 100 mg (Part 2)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 308 (11.36%)	38 / 370 (10.27%)	42 / 374 (11.23%)
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 308 (0.00%)	3 / 370 (0.81%)	2 / 374 (0.53%)
occurrences (all)	0	4	2
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	20 / 308 (6.49%)	17 / 370 (4.59%)	24 / 374 (6.42%)
occurrences (all)	20	18	24
Upper respiratory tract infection			
subjects affected / exposed	15 / 308 (4.87%)	20 / 370 (5.41%)	16 / 374 (4.28%)
occurrences (all)	15	21	17

Non-serious adverse events	Tildrakizumab 200 mg (Part 3)	Tildrakizumab 100 mg (Part 3)	Placebo (Part 1)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	86 / 360 (23.89%)	78 / 316 (24.68%)	23 / 154 (14.94%)
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	9 / 360 (2.50%)	9 / 316 (2.85%)	8 / 154 (5.19%)
occurrences (all)	9	9	8
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	44 / 360 (12.22%)	48 / 316 (15.19%)	8 / 154 (5.19%)
occurrences (all)	55	66	8

Upper respiratory tract infection subjects affected / exposed occurrences (all)	37 / 360 (10.28%) 43	26 / 316 (8.23%) 32	9 / 154 (5.84%) 10
---	-------------------------	------------------------	-----------------------

Non-serious adverse events	Tildrakizumab 100 mg (Part 1)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 309 (11.65%)		
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	2 / 309 (0.65%)		
occurrences (all)	2		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	24 / 309 (7.77%)		
occurrences (all)	26		
Upper respiratory tract infection			
subjects affected / exposed	10 / 309 (3.24%)		
occurrences (all)	10		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
12 September 2012	Tier 2 endpoints revised, PK, ADA timepoints revised
14 January 2014	New objectives were added
08 January 2018	Other secondary objectives and endpoints were added

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported